Literature DB >> 21900605

Metabolic state of glioma stem cells and nontumorigenic cells.

Erina Vlashi1, Chann Lagadec, Laurent Vergnes, Tomoo Matsutani, Kenta Masui, Maria Poulou, Ruxandra Popescu, Lorenza Della Donna, Patrick Evers, Carmen Dekmezian, Karen Reue, Heather Christofk, Paul S Mischel, Frank Pajonk.   

Abstract

Gliomas contain a small number of treatment-resistant glioma stem cells (GSCs), and it is thought that tumor regrowth originates from GSCs, thus rendering GSCs an attractive target for novel treatment approaches. Cancer cells rely more on glycolysis than on oxidative phosphorylation for glucose metabolism, a phenomenon used in 2-[(18)F]fluoro-2-deoxy-D-glucose positron emission tomography imaging of solid cancers, and targeting metabolic pathways in cancer cells has become a topic of considerable interest. However, if GSCs are indeed important for tumor control, knowledge of the metabolic state of GSCs is needed. We hypothesized that the metabolism of GSCs differs from that of their progeny. Using a unique imaging system for GSCs, we assessed the oxygen consumption rate, extracellular acidification rate, intracellular ATP levels, glucose uptake, lactate production, PKM1 and PKM2 expression, radiation sensitivity, and cell cycle duration of GSCs and their progeny in a panel of glioma cell lines. We found GSCs and progenitor cells to be less glycolytic than differentiated glioma cells. GSCs consumed less glucose and produced less lactate while maintaining higher ATP levels than their differentiated progeny. Compared with differentiated cells, GSCs were radioresistant, and this correlated with a higher mitochondrial reserve capacity. Glioma cells expressed both isoforms of pyruvate kinase, and inhibition of either glycolysis or oxidative phosphorylation had minimal effect on energy production in GSCs and progenitor cells. We conclude that GSCs rely mainly on oxidative phosphorylation. However, if challenged, they can use additional metabolic pathways. Therefore, targeting glycolysis in glioma may spare GSCs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21900605      PMCID: PMC3179043          DOI: 10.1073/pnas.1106704108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway.

Authors:  Min Fang; Zhirong Shen; Song Huang; Liping Zhao; She Chen; Tak W Mak; Xiaodong Wang
Journal:  Cell       Date:  2010-11-11       Impact factor: 41.582

Review 2.  Pyruvate kinase type M2 and its role in tumor growth and spreading.

Authors:  Sybille Mazurek; C Bruce Boschek; Ferdinand Hugo; Erich Eigenbrodt
Journal:  Semin Cancer Biol       Date:  2005-08       Impact factor: 15.707

3.  Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells.

Authors:  Michael F Clarke; John E Dick; Peter B Dirks; Connie J Eaves; Catriona H M Jamieson; D Leanne Jones; Jane Visvader; Irving L Weissman; Geoffrey M Wahl
Journal:  Cancer Res       Date:  2006-09-21       Impact factor: 12.701

Review 4.  Stem cells, cancer, and cancer stem cells.

Authors:  T Reya; S J Morrison; M F Clarke; I L Weissman
Journal:  Nature       Date:  2001-11-01       Impact factor: 49.962

5.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

Review 6.  Glycolysis, glutaminolysis and cell proliferation.

Authors:  W L McKeehan
Journal:  Cell Biol Int Rep       Date:  1982-07

7.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Authors:  Ingo K Mellinghoff; Maria Y Wang; Igor Vivanco; Daphne A Haas-Kogan; Shaojun Zhu; Ederlyn Q Dia; Kan V Lu; Koji Yoshimoto; Julie H Y Huang; Dennis J Chute; Bridget L Riggs; Steve Horvath; Linda M Liau; Webster K Cavenee; P Nagesh Rao; Rameen Beroukhim; Timothy C Peck; Jeffrey C Lee; William R Sellers; David Stokoe; Michael Prados; Timothy F Cloughesy; Charles L Sawyers; Paul S Mischel
Journal:  N Engl J Med       Date:  2005-11-10       Impact factor: 91.245

8.  Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.

Authors:  Gheeyoung Choe; Steve Horvath; Timothy F Cloughesy; Katherine Crosby; David Seligson; Aarno Palotie; Landon Inge; Bradley L Smith; Charles L Sawyers; Paul S Mischel
Journal:  Cancer Res       Date:  2003-06-01       Impact factor: 12.701

9.  Cancerous stem cells can arise from pediatric brain tumors.

Authors:  Houman D Hemmati; Ichiro Nakano; Jorge A Lazareff; Michael Masterman-Smith; Daniel H Geschwind; Marianne Bronner-Fraser; Harley I Kornblum
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-26       Impact factor: 11.205

10.  Identification of human brain tumour initiating cells.

Authors:  Sheila K Singh; Cynthia Hawkins; Ian D Clarke; Jeremy A Squire; Jane Bayani; Takuichiro Hide; R Mark Henkelman; Michael D Cusimano; Peter B Dirks
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

View more
  217 in total

1.  The RNA-binding protein Musashi-1 regulates proteasome subunit expression in breast cancer- and glioma-initiating cells.

Authors:  Chann Lagadec; Erina Vlashi; Patricia Frohnen; Yazeed Alhiyari; Mabel Chan; Frank Pajonk
Journal:  Stem Cells       Date:  2014-01       Impact factor: 6.277

Review 2.  Overcoming therapeutic resistance in glioblastoma: the way forward.

Authors:  Satoru Osuka; Erwin G Van Meir
Journal:  J Clin Invest       Date:  2017-02-01       Impact factor: 14.808

Review 3.  Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking?

Authors:  Nayoung Lee; Steven R Barthel; Tobias Schatton
Journal:  Lab Invest       Date:  2013-10-14       Impact factor: 5.662

4.  Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells.

Authors:  M Venere; P Hamerlik; Q Wu; R D Rasmussen; L A Song; A Vasanji; N Tenley; W A Flavahan; A B Hjelmeland; J Bartek; J N Rich
Journal:  Cell Death Differ       Date:  2013-10-11       Impact factor: 15.828

Review 5.  Can nanomedicines kill cancer stem cells?

Authors:  Yi Zhao; Daria Y Alakhova; Alexander V Kabanov
Journal:  Adv Drug Deliv Rev       Date:  2013-10-10       Impact factor: 15.470

6.  Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer.

Authors:  Le Zhang; Liang Xu; Fengchun Zhang; Erina Vlashi
Journal:  Cell Cycle       Date:  2016-10-18       Impact factor: 4.534

Review 7.  Metabolism and epigenetics of pancreatic cancer stem cells.

Authors:  M Perusina Lanfranca; J K Thompson; F Bednar; C Halbrook; C Lyssiotis; B Levi; T L Frankel
Journal:  Semin Cancer Biol       Date:  2018-09-28       Impact factor: 15.707

8.  PK-M2-mediated metabolic changes in breast cancer cells induced by ionizing radiation.

Authors:  Le Zhang; Justine Bailleul; Taha Yazal; Kevin Dong; David Sung; Amy Dao; Laura Gosa; David Nathanson; Kruttika Bhat; Sara Duhachek-Muggy; Claudia Alli; Milana Bochkur Dratver; Frank Pajonk; Erina Vlashi
Journal:  Breast Cancer Res Treat       Date:  2019-08-01       Impact factor: 4.872

9.  Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin.

Authors:  Eui Hyun Kim; Ji-Hyun Lee; Yoonjee Oh; Ilkyoo Koh; Jin-Kyoung Shim; Junseong Park; Junjeong Choi; Mijin Yun; Jeong Yong Jeon; Yong Min Huh; Jong Hee Chang; Sun Ho Kim; Kyung-Sup Kim; Jae-Ho Cheong; Pilnam Kim; Seok-Gu Kang
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

10.  Metabolic reprogramming orchestrates cancer stem cell properties in nasopharyngeal carcinoma.

Authors:  Yao-An Shen; Chia-Yu Wang; Yi-Tao Hsieh; Yann-Jang Chen; Yau-Huei Wei
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.